Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/29/2007WO2006124447A3 Substituted n-arylpyrrolidines as selective androgen receptor modulators
03/29/2007WO2006123255A3 Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
03/29/2007WO2006122250A3 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
03/29/2007WO2006122035A3 Method for treating central pain syndrome or for inducing centrally generated pain in an animal model
03/29/2007WO2006120705A3 Treatment and control of severe infections including cystic fibrosis
03/29/2007WO2006118719A3 Method of improving learning and memory in mammals
03/29/2007WO2006117761A3 Magnesium salts of hmg-coa reductase inhibitors
03/29/2007WO2006116661A3 Polyethylene glycol based composition for topical treatment of a closed wound with therapeutic pharmaceuticals
03/29/2007WO2006112714A3 Uronic acid and probiotics
03/29/2007WO2006110810A3 Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
03/29/2007WO2006110601A3 The genetic risk assessment in heart failure: impact of the genetic variation of nos3
03/29/2007WO2006109164A3 A method for preventing, delaying or reverting abnormal amyloid deposition
03/29/2007WO2006108965A3 Npy antagonists, preparation and use
03/29/2007WO2006108949A3 Novel use of zinc gluconate for treating hydradenitis suppurativa
03/29/2007WO2006108864A3 New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof
03/29/2007WO2006107655A3 Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
03/29/2007WO2006103568A3 NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF
03/29/2007WO2006102378A3 Drug delivery systems for treatment of diseases or conditions
03/29/2007WO2006101845A3 Synthesis and purification of pteroic acid and conjugates thereof
03/29/2007WO2006099325A3 Methods of treating ear infections
03/29/2007WO2006097768A3 Treatment of intestinal conditions by a compound which causes rna interference
03/29/2007WO2006096859A3 THE USE OF THIOPHOSPHONOFORMIC ACID AND NRTIs TO TREAT VIRAL INFECTIONS
03/29/2007WO2006096434A3 Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
03/29/2007WO2006094799A3 Pyridinone derivatives against malaria
03/29/2007WO2006094210A3 Tetrahydroquinoxalinone sirtuin modulators
03/29/2007WO2006091887A3 Methods of modulating tnf using bupropion
03/29/2007WO2006086454A3 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
03/29/2007WO2006084005A3 Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
03/29/2007WO2006081293A3 Delivery of bio-available compounds with anhydrous topical preparations
03/29/2007WO2006078676A3 Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
03/29/2007WO2006078287A3 Pde4b inhibitors and uses therefor
03/29/2007WO2006074443A3 Pde5 inhibitor compositions and methods for immunotherapy
03/29/2007WO2006063256A3 Treatment using d-threo methylphenidate
03/29/2007WO2006062883A3 Medical combinations
03/29/2007WO2006060424A3 Inducible nitric oxide synthase dimerization inhibitors
03/29/2007WO2006060079A3 Methods and compositions for treating nephrogenic diabetes insipidus
03/29/2007WO2006044771A3 Methods and compositions for reducing toxicity of a pharmaceutical compound
03/29/2007WO2006044155A3 Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
03/29/2007WO2006029209A3 Method for activating trpv4 channel receptors by agonists
03/29/2007WO2006028948A3 Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production
03/29/2007WO2006024841A3 Benzamide compounds
03/29/2007WO2006020652A3 Orally administered small peptides synergize statin activity
03/29/2007WO2006015872A9 Immune modulating oligonucleotides in connection with chemotherapeutic measures
03/29/2007WO2005120558A3 Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
03/29/2007WO2005112640A3 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
03/29/2007WO2005110410A3 Kinase inhibitors as therapeutic agents
03/29/2007WO2005109987A9 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders
03/29/2007WO2005107689A3 Cleansing and rinse solutions for skin and hair and method of using
03/29/2007WO2005097211A3 Compositions as adjuvants to improve immune responses to vaccines and methods of use
03/29/2007WO2005092066A8 Imidazole compounds
03/29/2007WO2005089522A3 Spermicidal and virucidal properties of various forms of sophorolipids
03/29/2007WO2005087199A8 Stabilised supersaturated solid solutions of steroidal drugs
03/29/2007WO2005016242A3 Synthetic process for trans-aminocyclohexyl ether compounds
03/29/2007US20070074300 Sialidase inhibitors for the treatment of cardiovascular disease
03/29/2007US20070073081 Peracetic acid in an anhydrous sterilant delivery system
03/29/2007US20070073077 Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof
03/29/2007US20070073061 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them
03/29/2007US20070073039 Peptides that inhibit viral infections
03/29/2007US20070073016 Polymer compositions for intraluminal stent
03/29/2007US20070072948 Composition comprising long-chain alcohols for suppressing concentrations of C-reactive protein (CRP) in human blood
03/29/2007US20070072947 Use of deoxypeganine for treating schizophrenic psychoses
03/29/2007US20070072946 Milnacipran for the long-term treatment of fibromyalgia syndrome
03/29/2007US20070072945 Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake
03/29/2007US20070072944 Amidoacetonitrile derivatives
03/29/2007US20070072943 Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
03/29/2007US20070072942 Statin derivatives
03/29/2007US20070072941 Suppression and prevention of tumors
03/29/2007US20070072940 Use of quinol derivatives thereof for cosmetic, dietary supplement or pharmaceutical compositions and compositions thereby obtained.
03/29/2007US20070072939 Cannabinoid active pharmaceutical ingredient for improved dosage forms
03/29/2007US20070072938 Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
03/29/2007US20070072937 Pharmaceutical composition comprising alpha-lipoic acid for inflammatory diseases
03/29/2007US20070072936 Androgen modulators
03/29/2007US20070072935 Catalytic antioxidants and methods of use
03/29/2007US20070072934 inhibitors of protein kinases and are useful in treating cancer; 4-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-3-methoxy-butyric acid; anticarcinogenic agent
03/29/2007US20070072933 Delivery of an ocular agent
03/29/2007US20070072932 Use of tyrosine kinase inhibitor to treat diabetes
03/29/2007US20070072931 Pharmaceutical composition and a method for treatment of prostate cancer
03/29/2007US20070072929 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-[(aminocarbonothioyl)amino]-4-oxobutanoate;potententiation; anaerobic/ aerobic microoraganisms; grampositive,gramnegative bacteria; Campylobacter; respiratory system disorders; paraciticides; nontoxic; enzymers/hydrolases/;enzyme inhibitors
03/29/2007US20070072928 treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one
03/29/2007US20070072927 Nutritional supplement for increased energy and stamina
03/29/2007US20070072926 Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases
03/29/2007US20070072925 Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase
03/29/2007US20070072924 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
03/29/2007US20070072923 Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde
03/29/2007US20070072922 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
03/29/2007US20070072921 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
03/29/2007US20070072920 Phenylethylamine analogs and their use for treating glaucoma
03/29/2007US20070072919 Preparing perindopril by reacting 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanine and octahydro 1H-indole-2-carboxylic acid or its ester with a uronium salt (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) in the presence of a tertiary amine in an aprotic solvent
03/29/2007US20070072918 3-[3-(4-chlorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-N-methyl-3-phenylpropan-1-amine; antidepressants; analgesics
03/29/2007US20070072917 Substituted 2-aminotetralin for the treatment of depression
03/29/2007US20070072916 Amino ceramide-like compounds and therapeutic methods of use
03/29/2007US20070072915 Novel phenoxyacetamide derivative and use thereof for preparation of diphenylamines
03/29/2007US20070072914 11- beta -hydroxysteroid dehydrogenase type 1 enzyme inhibitor; antidiabetic agent, antidepressant; metabolic syndrome, insulin resistance syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, atherosclerosis, dementia
03/29/2007US20070072913 Thermodynamically stable at room temperature, nonhygroscopic
03/29/2007US20070072912 Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants
03/29/2007US20070072911 Indoles and azaindoles as antiviral agents
03/29/2007US20070072910 Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
03/29/2007US20070072909 Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
03/29/2007US20070072908 Heterocyclic compounds
03/29/2007US20070072907 Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity